Novel Rx
Staying on Therapy in RA: Dr. Janet Pope
Dr. Janet Pope reviews abstract #0804 - Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands- presented at the ACR 2020 annual meeting.
At #ACR20 three different medications are reviewed in different studies to decrease the immunogenicity of pegloticase – Methotrexate, Azathioprine and Mycophenolate Mofetil.
Angus Worthing MD AngusWorthing
4 years 10 months ago
Today's #ACR20 lecture @r_burmester shows the biologic revolution was a result of serendipity -- this will spark the long-awaited new & improved name of our profession: serendipitology! Hi I'm Dr. Worthing I'm a Serendipitologist. I use drugs intended for infections, cancer etc.! https://t.co/buDqwAVK9u
Combination therapy with biologic and conventional DMARDs can be highly effective at inducing remission in patients with RA. Once controlled, patients are often interested in stopping combination drug therapy due to concerns related to medication burdens, side effect profiles, or safety.
Richard Conway RichardPAConway
4 years 10 months ago
After the SEAM-RA study, in patients taking MTX and ETN in sustained remission would you? #ACR20 @rheumnow
k dao KDAO2011
4 years 10 months ago
We have great options all around! Both are efficacious in biologic (TNFi) failures for RA patients.
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis Abst#0827 #ACR20 @RheumNow
https://t.co/1SsL9qLJD3
Olga Petryna DrPetryna
4 years 10 months ago
@RheumNow #ACR20 abs0710 early biologic therapy (BT) in JIA: Early BT=better outcome ( 81.8% on TNFi). BT start after 7,5mo from Dx correlates w/higher probability of active disease at 2 yrs (S=0,67 E=0,63). In active group at 2y 75% arthritis, 16,7% uveitis& 8,3% both. #ACRbest
Improving Drug Adherence in RA: Dr. Janet Pope
Dr. Janet Pope reviews abstract #0799 presented Saturday at the ACR 2020 annual meeting.
SEAM-RA Trial: Dr. Jeff Curtis
Dr. Jeff Curtis discusses abstract #0939, which looked at whether RA patients at or close to remission should continue taking their combination therapy, as presented at ACR 2020.
Janet Pope Janetbirdope
4 years 10 months ago
Is it time to change RA EULAR guidelines to reflect what we do? SEAM RCT showed withdrawal of MTX better than D/C etanercept in controlled RA. ETN alone =ETN+MTX. I vote to d/c the Rx that failed or by pt preference! Abstr#939 @RheumNow #ACR20 https://t.co/l9TNM3Gt0e
Dr. John Cush RheumNow
4 years 10 months ago
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow and its Faculty.
Eric Dein ejdein1
4 years 10 months ago
SEAM-RA trial Abst#0939 Combo TNF/MTX Rx -> ETN monoRx superior to MTX monoRx in sustaining remisson, simliar to staying on combo Rx. #ACR20 @RheumNow. Benefit of continuing combo: protect HACA Ab and longevity of TNFi https://t.co/Q934naKnBq
Richard Conway RichardPAConway
4 years 10 months ago
Dr Curtis presents SEAM-RA RCT of withdrawal of ETN or MTX in patients on combo therapy in sustained remission. 49.5% of ETN mono retained remission compared to 28.7% of MTX mono, and 52.9% who continued combo therapy. @rheumnow #ACR20 Abstr#939 #ACRbest https://t.co/wpAtBHJYUF
Dr. John Cush RheumNow
4 years 10 months ago
Listen to part I of our #ACR20 Day 1 recap. Listen through the link below or find us on Apple podcasts.
https://t.co/W6EMQiF9Rf https://t.co/R1ieCFnIxz
Janet Pope Janetbirdope
4 years 10 months ago
Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ
Poster Hall